28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Use of NSAIDs was associated with a lower risk of dementia (adjusted hazard ratio or aHR 0.76, 95% CI or CI 0.60-0.96) and, in particular, AD (aHR 0.63, CI 0.45-0.88), but not VaD (aHR 0.92, CI 0.65-1.28). 3 key findings →
Design: cohort study Participants: 3,229 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We identified a new genetic risk association of AD with rare coding CLU variations that is independent of the 5' common association signal identified in the GWA studies. 3 key findings →
Design: meta-analysis Participants: 1,930 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Association of HT use and risk of AD may depend on timing of use. 4 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Baseline assessments were conducted on 128 participants. 3 key findings →
Design: randomized controlled trial Participants: 125 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Over follow-up, 449 (18.3%) participants developed dementia. 2 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This retrospective cohort study is to investigate the association between herpes simplex virus (HSV) infections and dementia, and the effects of anti-herpetic medications on the risk involved, using Taiwan's National Health Insurance Research Database (NHIRD). 4 key findings →
Design: cohort study Participants: 33,448 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The overall unadjusted pooled odds ratio for the progression of MCI to dementia in people with diabetes/MetS was 1.67 (95% CI 1.27-2.19); the pooled odds ratio for progression in diabetes + MCI was 1.53 (95% CI 1.20-1.97) and in people with MetS + MCI was 2.95 (95% CI 1.23-7.05). 4 key findings →
Design: meta-analysis Participants: 15 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In older women, habitual sleep duration predicts the future risk for cognitive impairments including dementia, independent of vascular risk factors. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The study encompassed 284 cases with dementia and 1080 controls. 1 key finding →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Moreover, biomarker plasma levels and rates of change over time of participants who developed Alzheimer's disease dementia during follow-up were compared with age and sex-matched dementia-free control subjects. 5 key findings →
Participants: 549 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Of 31 624 156 adults discharged from French hospitals between 2008 and 2013, 1 109 343 were diagnosed with dementia and were included in the analyses. 2 key findings →
Design: retrospective cohort Participants: 156 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In this study, lower AD signature region volumes, brain microhemorrhages, higher WMH volumes, and infarcts were risk factors associated with dementia in older community-based residents. 4 key findings →
Design: cohort study Participants: 1,553 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
More than three quarters of this representative PD cohort developed dementia during the 8-year study period. 2 key findings →
Design: longitudinal study Participants: 224 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We estimated how all-cause mortality and cause-specific mortality in people with diabetes have changed over time, how the composition of the mortality burden has changed, and how this composition compared with that of the non-diabetes population. 2 key findings →
Design: longitudinal study Participants: 907 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The strength of the reported associations, the consistency across studies and the suggestion of a dose response supports a need to keep modifiable risk factor exposure to a minimum and to avoid exposure to additional modifiable risks. 3 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The incidence of dementia rises exponentially to the age of 90 years. 1 key finding →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Identification of individuals with increased risk of major adverse cardiovascular events (MACE) is important. 1 key finding →
Design: randomized controlled trial Participants: 18,548 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
IER is as effective as CER with regard to weight loss, insulin sensitivity and other health biomarkers, and may be offered as an alternative equivalent to CER for weight loss and reducing disease risk. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
We performed a systematic review and meta-analysis to explore whether type 2 diabetes mellitus (T2DM) increases the risk of Alzheimer's disease (AD). 3 key findings →
Design: systematic review Participants: 15 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Among 112 study participants with MCI, mean (SD) age was 76.6 (6.9) years, 55 were women (49.1%), and 27 progressed to dementia (24.1%), with an incidence rate of 121 per 1000 person-years. 3 key findings →
Design: cohort study Participants: 112 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Neuropsychiatric symptoms in MCI are associated with significantly an increased risk of incident dementia and AD. 5 key findings →
Design: cohort study Participants: 1,821 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We tested the hypothesis that a causal relationship exists between systolic BP (SBP) and/or diastolic BP (DBP) and risk of Alzheimer's disease (AD). 4 key findings →
Design: meta-analysis Participants: 299,024 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Socioeconomic factors and genetic predisposition are established risk factors for dementia. 4 key findings →
Design: cohort study Participants: 196,368 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Vaccines to prevent herpes zoster have been associated with reduced dementia risk. 5 key findings →
Design: cohort study Participants: 65,800 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 12,327 patients who underwent randomization (6162 to the asundexian group and 6165 to the placebo group), the incidence of ischemic stroke was lower in the asundexian group than in the placebo group (6.2% vs. 8.4%; cause-specific hazard ratio, 0.74; 95% confidence interval [CI], 0.65 to 0.84; P<0.001). 5 key findings →
Design: clinical trial Participants: 12,327 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
10 of the 3,281 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →